{"id":187,"date":"2015-03-20T00:27:54","date_gmt":"2015-03-20T00:27:54","guid":{"rendered":"http:\/\/depts.washington.edu\/uwviro\/wordpress\/?page_id=187"},"modified":"2024-06-24T16:54:46","modified_gmt":"2024-06-24T16:54:46","slug":"herpes-serologies","status":"publish","type":"page","link":"https:\/\/depts.washington.edu\/uwviro\/herpes-serologies\/","title":{"rendered":"Viral Serology"},"content":{"rendered":"\n
\n
SEARCH THE ONLINE LABORATORY TEST CATALOG<\/a><\/div>\n<\/div>\n\n\n\n
\n
\n
Expand All<\/a><\/div>\n<\/div>\n\n\n\n
\n

Cytomegalovirus (CMV)<\/h4>\n\n\n\n
\n

Cytomegalovirus (CMV) antibody screen is run 3 times daily on Monday through Friday. The antibody screen is a qualitative detection of CMV IgG class antibodies in human sera by the FDA approved DiaSorin CLIA (chemiluminescent immunoassay) test system.<\/p>\n\n\n\n

Search CMVS<\/a><\/strong> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Epstein Barr Virus (EBV)<\/h4>\n\n\n\n
\n

Epstein-Barr Virus virus detection is run weekly on Tuesday and is the qualitative detection of Epstein-Barr virus (EBV) Viral Capsid Antigen (VCA) IgG, VCA IgM, and Nuclear Antigen (EBNA) IgG class antibodies in human sera by the FDA approved Zeus ELISA (enzyme-linked immunosorbent assay) test system. Results are reported as either Reactive, Equivocal or NON-reactive.<\/p>\n\n\n\n

Search EBVEIA<\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis A<\/h4>\n\n\n\n
\n

Hepatitis A is a fecal-oral transmitted infection often acquired through contaminated food. Hepatitis A Virus or antigen detection is not done because viral shedding occurs in the weeks before clinical symptoms appear. Hepatitis A antibody testing is performed 2 times daily, Monday through Friday; IgM antibody tests are performed on all reactive specimens. Hepatitis A IgM indicates acute infection. All positive Hepatitis A IgM results are called to the requesting physician or laboratory and the local King County Dept. of Health. The physician must also report acute Hepatitis A infections to the local County Department of Public Health (in King County, telephone the Communicable Disease Department at (206) 296-4774). For vaccine recipients a Hepatitis A vaccine screen can be ordered. This assay does not include IgG\/IgM differentiation if positive.<\/p>\n\n\n\n

Search HAVIGG <\/strong><\/a>or HAVIGM <\/strong><\/a>code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis B<\/h4>\n\n\n\n
\n

Hepatitis B is transmitted through blood or secretions of infected patients. Infectivity of a patient is determined by enzyme immunoassay for Hepatitis B surface antigen (HBsAg), which is run Monday through Friday. Reports of reactive HBsAg are called to the ordering physician or laboratory and are automatically run for Hepatitis B viral DNA by PCR. Patients with needle sticks and other parenteral exposures need to receive Hepatitis B Immune Globulin within 72 hours of exposure. The routine HBsAg run can accommodate most specimens generated by accidental parenteral exposure. The physician must also report acute Hepatitis B infections to the local County Department of Public Health (in King County, telephone the Communicable Disease Department at (206) 296-4774).<\/p>\n\n\n\n

Note: Positive HBsAg will reflex to a Hepatitis B DNA by PCR at an additional charge.<\/p>\n\n\n\n

Search HBSAG <\/strong><\/a>or HBSAGX<\/strong><\/a> code in the online Laboratory Test Catalog.<\/p>\n\n\n\n

Search HBSS<\/strong><\/a> code in the online Laboratory Test Catalog for more information on Hepatitis B Surface Antigen & Antibody (HBsAg, HBsAb).
Search HBB<\/strong><\/a> code in the online Laboratory Test Catalog for more information on Hepatitis B Battery (HBSAb, HBSAg, and HBCAb).<\/p>\n\n\n\n

See Hepatitis B Chart 1<\/a>, Chart 2<\/a>, and Chart 3<\/a><\/span><\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis B Surface Antibody & Hepatitis B Core Antibody<\/h4>\n\n\n\n
\n

Hepatitis B surface antibody (anti-HBs) and Hepatitis B core antibody (anti-HBc) assays are useful for identifying persons susceptible to Hepatitis B infection (i.e. needle stick exposures), for documenting persons with past infection with Hepatitis B virus, for vaccine screening, and for determining response to vaccination. The Hepatitis B surface antibody result is reported international units (I.U.) of Hepatitis B surface antibody. Values above a test standard containing 10 I.U. of Hepatitis B surface antibody are considered protective levels. Vaccination\/re-vaccination is warranted with values below this level. Anti-HBs assays and anti-HBc assays are performed daily Monday through Friday.<\/p>\n\n\n\n

Search HBSA <\/strong><\/a>code in the online Laboratory Test Catalog for information on Hepatitis B Surface Antibody (HBsAb).<\/p>\n\n\n\n

Search HBCA <\/strong><\/a>code in the online Laboratory Test Catalog for information on Hepatitis B Core Antibody (HBcAb).<\/p>\n\n\n\n

Search HBSS<\/strong><\/a> code in the online Laboratory Test Catalog for more information on Hepatitis B Surface Antigen & Antibody (HBsAg, HBsAb).
Search HBB<\/strong><\/a> code in the online Laboratory Test Catalog for more information on Hepatitis B Battery (HBSAb, HBSAg, and HBCAb).<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis B Core IgM Antibodies<\/h4>\n\n\n\n
\n

Presence of Hepatitis B core IgM antibodies helps to distinguish chronic carriers of HBsAg from acute cases of Hepatitis B. Persons with recent exposure to Hepatitis B will be reactive for core IgM, while chronic carriers of HBsAg will not. This test is sent out to a Reference lab.<\/p>\n\n\n\n

Search RHBCAM<\/b><\/a> code in the online Laboratory Test Catalog for information on Hepatitis B Core IgM Antibody.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis B ‘e’ Antigen and Antibody<\/h4>\n\n\n\n
\n

The Qualitative detection of Hepatitis B virus \u201ce\u201d antigen (HBeAg) and Hepatitis B virus \u201ce\u201d antibody (HBeAb) in human sera is performed by the FDA approved DiaSorin CLIA (chemiluminescent immunoassay), daily Mon \u2013 Fri.<\/p>\n\n\n\n

The presence of HBeAg in serum is associated with presence of Dane particles and Hepatitis B virus (HBV) DNA polymerase enzyme. These markers suggest active HBV replication. Hepatitis B Surface antigen (HBsAg) positive and HBeAg positive persons are much more likely to transmit infections to others. The development of anti-HBe during acute Hepatitis B infection is a marker of resolution of illness.<\/p>\n\n\n\n

Search HBE<\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Hepatitis C Virus (HCV)<\/h4>\n\n\n\n
\n

Hepatitis C is the leading cause of post transfusion hepatitis and of “non-A, non-B” hepatitis. It may be acquired by blood products or by non-parenteral routes. Most HCV infections are sub-clinical, and chronic hepatitis is common. All positive Hepatitis C antibodies are confirmed by PCR at an additional charge. Hepatitis C Antibody screens are run daily, Mon. – Sat.<\/p>\n\n\n\n

Search HCAB<\/a> or HCABX <\/a>code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Herpes Simplex Virus types 1 and 2 by Western Blot<\/h4>\n\n\n\n
\n

Viral isolation and subsequent subtyping is generally the best way to document an acute HSV infection. However, serologies for HSV are useful in determining whether a person has had a past infection with HSV-1 or HSV-2, and is the best way to detect “silent carriers” of HSV-2. Our laboratory detects HSV Antibodies by Western blot assay, which is not only highly sensitive for detecting HSV antibodies, but also is highly accurate in differentiating past HSV-1 from HSV-2 infections and determining whether someone has antibodies to both viruses.<\/p>\n\n\n\n

The specificity of the Western blot assay provides an accurate distinction in 99% of patients between antibody to HSV-1 and antibodies to HSV-2. In addition, Western blot readily documents seroconversion. Since fewer than 5% of patients demonstrate a detectable rise in antibody titer during recurrent HSV episodes, an interpretive report is given instead of numerical values. HSV Western blot serologies are run three times a week. Most results are available within five days. If the antibody subtype is unclear (about 20% of specimens), the serum will be adsorbed against HSV-1 and HSV-2 proteins and re-tested. This requires an additional week. Call Reference Laboratory Services<\/a> if you have further questions, (800) 713-5198.<\/p>\n\n\n\n

This Western blot assay detects IgG antibody. HSV IgM antibody is present during both primary and recurrent infections making result interpretation difficult. For infants with suspected HSV disease, viral culture and PCR tests should be performed.<\/p>\n\n\n\n

Search HSWB <\/strong><\/a>or HSWBP<\/a><\/strong> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Measles<\/h4>\n\n\n\n
\n

Measles is a contagious respiratory infection causing a total-body skin rash and flu-like symptoms. Measles is rare in the United States thanks to widespread immunization yet millions of cases happen worldwide every year. <\/span><\/span>Measles Immune Status test is a qualitative detection of Rubeola (Measles) IgG class antibodies in human sera by the FDA approved DiaSorin CLIA (chemiluminescent immunoassay) test system and are run daily Mon – Fri.<\/p>\n\n\n\n

Search RBIS <\/b><\/a>code in the online Laboratory Test Catalog for information.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Mumps<\/h4>\n\n\n\n
\n

Initial mumps symptoms are non-specific and include fever, headache, malaise, muscle pain, and loss of appetite. These symptoms are usually followed by painful swelling of the parotid glands, called parotitis, which is the most common symptom of infection. Mumps Immune Status test is a<\/span><\/span> qualitative detection of Mumps IgG class antibodies in human sera by the FDA approved DiaSorin CLIA (chemiluminescent immunoassay) test system and are run daily Mon – Fri.<\/p>\n\n\n\n

Search MPIS<\/b><\/a> code in the online Laboratory Test Catalog for information.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

TB Quantiferon<\/h4>\n\n\n\n
\n

This test is for the diagnosis of latent TB (tuberculosis) infection, but not of active TB disease. Most people who breathe in TB bacteria and become infected have a body that is able to fight the bacteria to stop them from growing. Many people who have latent TB infection never develop TB disease. In these people, the TB bacteria remain inactive for a lifetime without causing disease.<\/p>\n\n\n\n

Search QFTB<\/b><\/a> code in the online Laboratory Test Catalog for information.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Rubella<\/h4>\n\n\n\n
\n

The quantitative detection of Rubella IgG class antibodies in human sera by the FDA approvedDiaSorin CLIA (chemiluminescent immunoassay) test system and are run daily Mon – Fri. Results are reported as IU\/mL.<\/p>\n\n\n\n

Search RUIS<\/b><\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

SARS-CoV-2 Nucleocapsid Antibody IgG<\/h4>\n\n\n\n
\n

The Abbott Architect SARS-CoV-2 IgG assay, run under an emergency use authorization from the FDA, is a qualitative test designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2 in serum and plasma from patients who are suspected of past coronavirus disease (COVID-19) or in serum and plasma of subjects that may have been infected by SARS-CoV-2.<\/span><\/p>\n\n\n\n

Search NCVIGG<\/b><\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

SARS-CoV-2 Antibody, IgG Immune Status (Nucleocapsid & Quant. anti-Spike)<\/h4>\n\n\n\n
\n

A battery of tests to determine SARS-CoV-2 immune status. The Abbott Architect SARS-CoV-2 IgG assay, run under an emergency use authorization from the FDA, is a qualitative test designed to detect IgG antibodies to the nucleocapsid protein of SARS-CoV-2. The Abbott Architect SARS-CoV-2 IgG II assay, run under an emergency use authorization from the FDA, is a quantitative test designed to detect IgG antibodies to the spike protein of SARS-CoV-2 in serum and plasma. Results are reported as AU\/mL. Per manufacture\u2019s package insert protective level is \u226550.0 AU\/mL.<\/p>\n\n\n\n

Search NCVIGB<\/b><\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

SARS-CoV-2 Spike Antibody<\/h4>\n\n\n\n
\n

The Abbott Architect SARS-CoV-2 IgG II assay, run under an emergency use authorization from the FDA, is quantitative test designed to detect IgG antibodies to the spike protein of SARS-CoV-2 in serum and plasma from individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are reported as AU\/mL.<\/p>\n\n\n\n

Search NCVIGQ<\/b><\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n

Varicella Zoster Virus (VZV)<\/h4>\n\n\n\n
\n

The Varicella Zoster Virus (VZV) antibody screen is done by the DiaSorin CLIA (chemiluminescent immunoassay) test system to determine the immune status of individual with respect to VZV. It is particularly useful for immunocompromised or pregnant patients who are at risk of developing severe Varicella disease and who, if negative, may be candidates for Varicella Zoster Immune Globulin (VZIG). It is also useful for screening health care providers who may be exposed to the disease. VZIG must be given within 72 hours of exposure. The VZV antibody screen is run daily Mon – Fri.<\/p>\n\n\n\n

Search VZIS<\/b><\/a> code in the online Laboratory Test Catalog.<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Cytomegalovirus (CMV) Cytomegalovirus (CMV) antibody screen is run 3 times daily on Monday through Friday. The antibody screen is a qualitative detection of CMV IgG class antibodies in human sera by the FDA approved DiaSorin CLIA (chemiluminescent immunoassay) test system. Search CMVS code in the online Laboratory Test Catalog. Epstein Barr Virus (EBV) Epstein-Barr Virus […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"class_list":["post-187","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/pages\/187","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/comments?post=187"}],"version-history":[{"count":37,"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/pages\/187\/revisions"}],"predecessor-version":[{"id":2378,"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/pages\/187\/revisions\/2378"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/uwviro\/wp-json\/wp\/v2\/media?parent=187"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}